Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
A total of 50 patients >40 yrs of age with an expected hospital stay in the Medical Intensive
Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The
patient and study team will be blinded to which drug they are receiving (either Arixtra or
Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive
drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed
by the study team approximately 30 days after discharge from the hospital.